Abstract #0183

In vivo 1H MRS and MRI longitudinal assessment of GBM mouse xenografts derived from freshly injected human cells

Marta Lai¹, Cristina Cudalbu², Marie-France Hamou^3,4, Mario Lepore², Lijing Xin², Roy Thomas Daniel⁴, Andreas Felix Hottinger⁵, Monika Hegi^3,4, and Rolf Gruetter^1,6,7

¹Laboratory of Functional and Metabolic Imaging (LIFMET), Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland, ²Animal Imaging and Technology Core (AIT), Center for Biomedical Imaging (CIBM), Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland, ³Laboratory of Brain Tumor Biology and Genetics, Neuroscience Research Center, Lausanne University Hospital (CHUV), Lausanne, Switzerland, ⁴Service of Neurosurgery, Department of Clinical Neurosciences, Lausanne University Hospital (CHUV), Lausanne, Switzerland, ⁵Service of Neurology, Department of Clinical Neurosciences, Lausanne University Hospital (CHUV), Lausanne, Switzerland, ⁶Department of Radiology, University of Geneva, Geneva, Switzerland, ⁷Department of Radiology, University of Lausanne, Lausanne, Switzerland

In the present study orthotopic xenograft mice models of glioblastoma (GBM) derived from freshly dissected human cells of three different patients were compared at the aim of assessing patient-to-patient variability related to tumor metabolism and structural development. Mice were followed longitudinally in vivo in a 14.1 Tesla scanner with MRI and ¹H MRS which allowed to precisely quantify a wide range of GBM biomarkers. Finally spectra examined at late stage revealed peculiarity linked to each patient-derived xenograft, while longitudinal evolution of GBM biomarkers showed a close similarity in their expression within the same group and in animal lifespan.

This abstract and the presentation materials are available to members only; a login is required.

Join Here